文献速递前列腺增生与排尿功能障碍男科与性医学

5α-还原酶抑制剂与抑郁无关联

Lack of Association between 5α-Reductase Inhibitors and Depression.
PubMed 文献 · J Urol · 2020-04-15

基于美国退伍军人健康管理局2014财年53848例启动5α-还原酶抑制剂治疗的男性患者数据,采用序列对称性分析评估抑郁风险。结果显示启动药物后一年内抗抑郁药处方和抑郁诊断的对称比分别为0.84(95%CI 0.80-0.89)和0.83(95%CI 0.79-0.86),均未显示抑郁风险增加。α1-肾上腺素受体拮抗剂对照分析结果类似(SR 0.87,95%CI 0.84-0.90)。

要点

  • 5α-还原酶抑制剂启动后抑郁风险未增加,对称比<1。
  • 抑郁可能更多归因于良性前列腺增生及相关下尿路症状。
  • α1-肾上腺素受体拮抗剂对照分析结果与5α-还原酶抑制剂一致。

核心结论

  • 启动5α-还原酶抑制剂与抑郁风险增加无关。
  • 抑郁更可能归因于良性前列腺增生及相关下尿路症状而非5α-还原酶抑制剂暴露。

研究设计与样本

  • 使用美国退伍军人健康管理局行政数据,识别2014财年启动5α-还原酶抑制剂治疗的53848例男性患者。
  • 采用序列对称性分析,分别以抗抑郁药处方和抑郁诊断评估新发抑郁事件。
  • 在启动α1-肾上腺素受体拮抗剂的退伍军人中进行了相同的暴露反事实分析。

主要发现

  • 启动5α-还原酶抑制剂后新发抗抑郁药处方2563例,启动前3051例(SR 0.84,95%CI 0.80-0.89)。
  • 新发抑郁诊断的对称比为0.83(95%CI 0.79-0.86)。
  • 按年龄组、5α-还原酶抑制剂种类、抗抑郁药类别、既往α1-肾上腺素受体拮抗剂暴露和抑郁诊断类型分层均未显示正关联。
  • α1-肾上腺素受体拮抗剂分析结果几乎相同(SR 0.87,95%CI 0.84-0.90)。

临床怎么用

  • 临床中不应因抑郁风险顾虑而避免使用5α-还原酶抑制剂。
  • 对于良性前列腺增生患者出现抑郁症状,应评估下尿路症状等潜在因素而非归因于药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Depressed mood and suicidality reported with 5α-reductase inhibitors (finasteride and dutasteride) during post-marketing surveillance resulted in the addition of depression risk to finasteride labeling. As peer reviewed studies are limited and have reported mixed findings, we further evaluated 5α-reductase inhibitor exposure and depression risk using sequence symmetry analysis. MATERIALS AND METHODS: National Veterans Health Administration administrative data were used to identify 53,848 male patients initiating 5α-reductase inhibitor therapy during fiscal year 2014. Incident depression events were assessed separately using the 2 measures of antidepressant prescription and depression diagnosis. Symmetry ratios were calculated as the ratio of patients with an incident depression event in the year following 5α-reductase inhibitor initiation to the year preceding initiation. An identical exposure counterfactual analysis was conducted among veterans initiating α1-adrenergic receptor antagonists. RESULTS: Incident antidepressant prescribing was observed in 2,563 patients following 5α-reductase inhibitor initiation and 3,051 patients preceding 5α-reductase inhibitor initiation (SR 0.84, 95% CI 0.80-0.89). Similar findings were observed for incident depression diagnosis (SR 0.83, 95% CI 0.79-0.86). Stratification by age group, 5α-reductase inhibitor agent, antidepressant class, prior α1-adrenergic receptor antagonist exposure and depression diagnosis type failed to demonstrate any positive association between 5α-reductase inhibitor and depression. Nearly identical results were observed in the α1-adrenergic receptor antagonist analysis (SR 0.87, 95% CI 0.84-0.90). CONCLUSIONS: Initiation of a 5α-reductase inhibitor was not associated with increased risk of depression. Our findings support the hypothesis that depression is more likely attributable to underlying benign prostatic hyperplasia and associated lower urinary tract symptoms than 5α-reductase inhibitor exposure.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Dyson TE, Cantrell MA, Lund BC, et al. Lack of Association between 5α-Reductase Inhibitors and Depression. J Urol. 2020. PMID: 32294395. doi:10.1097/JU.0000000000001079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。